CellCarta Adds Tempus to Companion Diagnostics Commercialization Network
CellCarta has partnered with Tempus to enhance oncology diagnostics within its CDx Accelerator Model. Tempus becomes the second commercial laboratory in the network.
Montreal, August 6, 2026 – CellCarta, a global contract research organization (CRO) supporting the biopharmaceutical industry, today announced a strategic partnership with Tempus. This collaboration expands CellCarta's CDx Accelerator Model, focusing on the commercialization of oncology-focused companion diagnostics (CDx).
Tempus joins as the second commercial laboratory partner within CellCarta's network for this model. The collaboration aims to improve access for cancer patients to advanced diagnostic tests that support targeted therapies.
CellCarta's CDx Accelerator Model is designed to assist pharmaceutical companies in accelerating the development and commercialization of diagnostic tests. The integration of Tempus provides CellCarta with additional expertise and technology, expected to facilitate a faster market entry for new diagnostic solutions in the cancer field.
The partnership represents a significant step for CellCarta in expanding its capabilities for commercializing diagnostic tests. It supports biopharmaceutical companies in developing and launching innovative tools crucial for advancements in precision medicine.